Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Alessandra Tucci, MD, Alessandro Re, MD, Chiara Pagani, MD, Anna Guidetti, Anna Dodero, Fabrizio Marino, MD, Ivana Casaroli, MD, Giulia Soverini, MD, Rosa Daffini, MD, Monica Balzarotti, Giulia Campostrini, Luisa Lorenzi, MD, Piera Balzarini, Fabio Facchetti, Carmelo Carlo-Stella, MD, Paolo Corradini, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139977

Published: 2020

Journal Articles

Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases

Chiara Cattaneo, Valeria Cancelli, MD, Chiara Pagani, MD, Alessandra Tucci, MD, Giuseppe Rossi, MD, Luisa Imberti, MD, Alessandra Sottini, BS, Kerry Dobbs, BS, Elana Shaw, BS, Luigi D. Notarangelo, MD, Jeffrey Cohen, MD, Peter Burbelo, PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-141355

Published: 2020

Journal Articles

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Samantha Ferrari, MD, Chiara Pagani, MD, Mariella D'Adda, MD, Nicola Bianchetti, MD, Annamaria Pelizzari, MD, Doriana Gramegna, MD, Chiara Bottelli, MD, Luisa Lorenzi, MD, Gabriella Vona, Alessandra Tucci, MD, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-139431

Published: 2020

Journal Articles

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Chiara Pagani, MD, Monica Fumagalli, MD, Patrizia Zappasodi, MD, Erika Borlenghi, MD, Alessandro Re, MD, Fabio Ciceri, MD, Margherita Sciumé, Roberto Cairoli, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 3603.

https://doi.org/10.1182/blood-2019-125288

Published: 2019

Journal Articles

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Erika Borlenghi, MD, Chiara Pagani, MD, Michele Malagola, MD, Diego Bertoli, PhD, Francesca Schieppati, MD, Silvana Archetti, PhD, Angela Passi, MD, Cinzia Lamorgese, Chiara Cattaneo, MD, Nicola Polverelli, Margherita Sciumé, Rosa Daffini, MD, Doriana Gramegna, MD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 2695.

https://doi.org/10.1182/blood-2019-126074

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Isavuconazole in Hematological Patients: Results of a Real-Life Multicenter Seifem Study

Blood (2018) 132 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2018-99-113772

Published: 2018

Journal Articles

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Alessandro Re, MD, Nicola Bianchetti, Chiara Cattaneo, MD, Salvatore Casari, MD, Chiara Pagani, MD, Annalisa Peli, MD, Emanuele Focà, MD, Pierino ferremi Leali, MD, Camillo Almici, MD, Francesco Castelli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2018-99-116816

Published: 2018

Journal Articles

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Nicola Bianchetti, Alessandra Tucci, Alessandro Re, MD, Chiara Pagani, MD, Chiara Cattaneo, MD, Maria Miscio, Fabio Facchetti, Simona Fisogni, MD, Piera Balzarini, Domenico Albano, Giovanni Bosio, Francesco Bertagna, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2018-99-119090

Published: 2018

Journal Articles

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

Chiara Cattaneo, MD, Doriana Gramegna, Chiara Pagani, MD, Erika Borlenghi, Michele Malagola, MD, Elisa Cerqui, MD, Angela Passi, MD, Francesca Schieppati, MD, Claudia Crippa, MD, Daniela Dalceggio, Cecilia Carbone, MD, Anna Maria Pelizzari, Margherita Sciumé, Alessandro Re, MD, Domenico Russo, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 2288.

https://doi.org/10.1182/blood.V130.Suppl_1.2288.2288

Published: 2017

Journal Articles

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Mariella D'adda, Mirko Farina, MD, Francesca Schieppati, MD, Elisa Cerqui, MD, Giuseppina Ruggeri, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 1589.

https://doi.org/10.1182/blood.V130.Suppl_1.1589.1589

Published: 2017

Journal Articles

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

Erika Borlenghi, MD, Mirko Farina, MD, Angela Passi, MD, Chiara Pagani, MD, Elisa Cerqui, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marta Petullà, PharmD, Angelo Belotti, MD, Giuseppina Ruggeri, Giuseppe Rossi, MD

Blood (2016) 128 (22): 3993.

https://doi.org/10.1182/blood.V128.22.3993.3993

Published: 2016

Journal Articles

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

Blood (2016) 128 (22): 3096.

https://doi.org/10.1182/blood.V128.22.3096.3096

Published: 2016

Journal Articles

Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL)

Chiara Rusconi, MD, Antonella Anastasia, MD, Annalisa Chiarenza, Luigi Marcheselli, Federica Cavallo, Sara Rattotti, Barbara Botto, Angela Ferrari, Manuela Zanni, Marco Calabrese, Chiara Pagani, MD, Erika Meli, MD, Massimo Federico, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 3933.

https://doi.org/10.1182/blood.V126.23.3933.3933

Published: 2015

Journal Articles

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Marina Motta, MD, Marco Chiarini, MSC, Marta Petullà, PharmD, Claudia Ghidini, BSC, Marion Vaglio Tessitore, BSC, Viviana Giustini, MSC, Chiara Pagani, MD, Antonella Anastasia, MD, Samantha Ferrari, MD, Alessandra Tucci, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 1531.

https://doi.org/10.1182/blood.V126.23.1531.1531

Published: 2015

Journal Articles

Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease

Cristina Skert, MD, Alessandro Turra, Michele Malagola, Simone Perucca, Valeria Cancelli, Rosa Daffini, Rossella Ribolla, Cesare Bergonzi, Carla Filì, MD, Chiara Pagani, MD, Andrea Di Palma, Federica Cattina, MD PhD, Simona Bernardi, Domenico Russo, MD PhD

Blood (2014) 124 (21): 3932.

https://doi.org/10.1182/blood.V124.21.3932.3932

Published: 2014

Journal Articles

Secondary Acute Myeloid Leukemia Is an Heterogeneous Subgroup of Elderly AML Where Patient’s Fitness Criteria and ELN Prognostic Stratification Can be Applied to Guide Treatment Decisions: An Analysis of 127 Patients By the Network Rete Ematologica Lombarda (REL)

Erika Borlenghi, MD, Chiara Pagani, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Matteo Carrabba, MD, Nicola Fracchiolla, MD, Francesca Guidotti, MD, Laura Marbello, MD, Andrea Ferrario, MD, Silvia Ferrari, MD, Francesca Schieppati, MD, Daniela Dalceggio, MD, Giuseppe Rossi, MD

Blood (2014) 124 (21): 953.

https://doi.org/10.1182/blood.V124.21.953.953

Published: 2014

Journal Articles

WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia

Michele Malagola, Crisitina Skert, Enrico Morello, MD, Francesca Antoniazzi, MD, Erika Borlenghi, MD, Alessandro Turra, Chiara Pagani, MD, Rossella Ribolla, Valeria Cancelli, Federica Cattina, MD PhD, Elisa Alghisi, Simona Bernardi, Simone Perucca, Andrea Di Palma, Giuseppina Ruggeri, Giuseppe Rossi, Luigi Caimi, Domenico Russo, MD

Blood (2014) 124 (21): 3695.

https://doi.org/10.1182/blood.V124.21.3695.3695

Published: 2014

Journal Articles

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

Erika Borlenghi, MD, Chiara Pagani, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Nicola Fracchiolla, MD, Francesca Guidotti, MD, Laura Marbello, MD, Andrea Ferrario, MD, Carlo Messina, MD, Emanuele Ravano, MD, Cinzia Lamorgese, Marta Petullà, Giuseppe Rossi, MD

Blood (2014) 124 (21): 279.

https://doi.org/10.1182/blood.V124.21.279.279

Published: 2014

Journal Articles

90Yttrium-Ibritumomab Tiuxetan for Non-Hodgkin Lymphoma: Results after a Median Follow-up of 5 Years in a Single Institution

Antonella Anastasia, Enrico Morello, MD, Alessandra Tucci, MD, Alessandro Re, MD, Marina Motta, MD, Chiara Pagani, MD, Raffaele Giubbini, Giancarlo Magri, Marta Petullà, Giuseppe Rossi, MD

Blood (2014) 124 (21): 4455.

https://doi.org/10.1182/blood.V124.21.4455.4455

Published: 2014

NARROW

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Isavuconazole in Hematological Patients: Results of a Real-Life Multicenter Seifem Study

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL)

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease

Secondary Acute Myeloid Leukemia Is an Heterogeneous Subgroup of Elderly AML Where Patient’s Fitness Criteria and ELN Prognostic Stratification Can be Applied to Guide Treatment Decisions: An Analysis of 127 Patients By the Network Rete Ematologica Lombarda (REL)

WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

90Yttrium-Ibritumomab Tiuxetan for Non-Hodgkin Lymphoma: Results after a Median Follow-up of 5 Years in a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only